Codagenix Collaborates with Serum Institute of India to Co-Develop a Live-Attenuated Vaccine Against Coronavirus (COVID-19)

 Codagenix Collaborates with Serum Institute of India to Co-Develop a Live-Attenuated Vaccine Against Coronavirus (COVID-19)

Codagenix Collaborates with Serum Institute of India to Co-Develop a Live-Attenuated Vaccine Against Coronavirus (COVID-19)

Shots:

  • Codagenix will utilize its deoptimization technology for viral deoptimization, designed several nCoV vaccine candidate genomes, will grow and conduct in-vivo tests of vaccine viruses prior to testing in clinical studies
  • The Serum Institute of India will scale up the manufacturing of vaccines to ensure its availability to meet the public needs. The companies are pursuing an accelerated development pathway to speed up the availability of vaccine
  • The focus of the collaboration is to develop a live-attenuated vaccine, inducing an immune response to multiple antigens of the virus and enables scale for mass production

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Codagenix

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post